Commentary: Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

• Type of Material: Article
• Authors: Nabil Saba, Emory University
• Language: English
• Date: 2017-03-13
• Publisher: FRONTIERS MEDIA SA
• Publication Version: Final Published Version
• Copyright Statement: © 2017 Saba.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.3389/fonc.2017.00031
• Title of Journal or Parent Work: FRONTIERS IN ONCOLOGY
• Volume: 7
• Issue: MAR
• Start Page: 31
• End Page: 31
• Keywords: Oncology; Life Sciences & Biomedicine; Science & Technology
• Research Categories: Health Sciences, Oncology

Abstract

Commentary